Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Rigel Pharmaceuticals Inc Transaction History

Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main

$94.9 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2024	SELL	$1.25 - $2.0 $477,555 - $764,088	-382,044 Reduced 17.33%	1,822,376 $2.41 Million
Q1 2023 May 15, 2023	SELL	$1.25 - $2.0 $477,555 - $764,088	-382,044 Reduced 17.33%	1,822,376 $2.41 Million
Q4 2022 May 17, 2024	BUY	$0.67 - $11.9 $1.48 Million - $26.2 Million	2,204,420 New	2,204,420 $3.31 Million
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $982,327 - $17.4 Million	1,466,160 Added 198.6%	2,204,420 $3.31 Million
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $812,086 - $9.01 Million	738,260 New	738,260 $871,000
Q2 2018 Aug 14, 2018	SELL	$2.83 - $4.11 $566,000 - $822,000	-200,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.54 - $4.54 $708,000 - $908,000	200,000 New	200,000 $708,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.

Account